Search research articles
Contact Us
Filters
Showing results (31-40 of 94) with videos related to
Page
of 10
Sort By:
Investigational New Drugs
|
February 18, 2018
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study
Anastasios Stathis, Ian W Flinn, Sumit Madan, et al.
Leukemia & Lymphoma
|
January 15, 2016
A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
Kami Maddocks, Erin Hertlein, Timothy L Chen, et al.
Blood
|
October 31, 2014
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma
Kami Maddocks, Beth Christian, Samantha Jaglowski, et al.
Therapeutic Advances in Hematology
|
July 28, 2022
Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study
Megan Fleming, Ying Huang, Emily Dotson, et al.
Blood Advances
|
November 17, 2021
Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas
Megan Fleming, Ying Huang, Emily Dotson, et al.
Blood Advances
|
October 26, 2022
Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy
Kaitlin Annunzio, Michael Cackovic, David Bond, et al.
Frontiers in Oncology
|
October 2, 2023
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with Waldenstrom macroglobulinemia
Ansel Nalin, Qiuhong Zhao, Timothy Voorhees, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 1, 2024
Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma
Matthew Mei, Ni-Chun Tsai, Joycelynne Palmer, et al.
The Lancet. Haematology
|
October 11, 2021
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study
Sarah C Rutherford, Jeremy S Abramson, Nancy L Bartlett, et al.
Leukemia
|
July 16, 2022
Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib
Audrey M Sigmund, Ying Huang, Amy S Ruppert, et al.
Page
of 10
Search research articles
Search
Showing results (31-40 of 94) with videos related to
Sort By:
Page
of 10
Investigational New Drugs
|
February 18, 2018
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study
Anastasios Stathis, Ian W Flinn, Sumit Madan, et al.
Leukemia & Lymphoma
|
January 15, 2016
A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
Kami Maddocks, Erin Hertlein, Timothy L Chen, et al.
Blood
|
October 31, 2014
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma
Kami Maddocks, Beth Christian, Samantha Jaglowski, et al.
Therapeutic Advances in Hematology
|
July 28, 2022
Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study
Megan Fleming, Ying Huang, Emily Dotson, et al.
Blood Advances
|
November 17, 2021
Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas
Megan Fleming, Ying Huang, Emily Dotson, et al.
Blood Advances
|
October 26, 2022
Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy
Kaitlin Annunzio, Michael Cackovic, David Bond, et al.
Frontiers in Oncology
|
October 2, 2023
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with Waldenstrom macroglobulinemia
Ansel Nalin, Qiuhong Zhao, Timothy Voorhees, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 1, 2024
Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma
Matthew Mei, Ni-Chun Tsai, Joycelynne Palmer, et al.
The Lancet. Haematology
|
October 11, 2021
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study
Sarah C Rutherford, Jeremy S Abramson, Nancy L Bartlett, et al.
Leukemia
|
July 16, 2022
Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib
Audrey M Sigmund, Ying Huang, Amy S Ruppert, et al.
Page
of 10